Please login to the form below

Not currently logged in
Email:
Password:

Retroviruses found in chronic fatigue cases

In a recent study, almost 90 per cent of CFS patients showed signs of infection with a group of mouse leukaemia viruses

In a recent study, almost 90 per cent of patients with chronic fatigue syndrome (CFS) showed signs of infection with retroviruses, suggesting that antiviral drugs could be used to treat the disease.

In the US government study, researchers identified at least one of four different murine-related leukaemia viruses in 86.5 per cent of the 37 patients with CFS compared to 6.8 per cent of 44 patients without the disease.

The results suggest antiviral drugs including Merck's Isentress (raltegravir) and Gilead Science's Viread (tenofovir) should be tested for the condition.

The study published in the Proceedings of the National Academy of Sciences, supports findings from last year that linked CFS to a related infectious agent, called XMRV. But they are contrary to last month's report from the US Centers for Disease Control and Prevention that failed to find a viral link.

Murine-related leukaemia is a form of an infectious agent known to cause leukaemia and other cancers in mice. Whether it causes diseases in humans is not known.

CFS affects around 17 million people worldwide.

24th August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics